Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: A case report

Journal of Korean Medical Science

Volumn 21, Issue 6, 2006, Pages 1124-1127

  You, Chan Ran ^a   Kim, Hae Rim ^b   Yoon, Chong Hyeon ^a   Lee, Sang Heon ^b,c   Park, Sung Hwan ^a   Kim, Ho Youn ^a  

^a The Catholic University of Korea   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Konkuk University Hospital   (South Korea)

Author keywords

Arthritis, juvenile rheumatoid; Cyclosporine; Macrophage activation syndrome

Indexed keywords

EID: 33845875760     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.6.1124     Document Type: Article

References (15)

1. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 548-52.
2. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996; 129: 630-2.
3. Brewer EJ Jr, Bass J, Baum J, Cassidy JT, Firk C, Jacobs J, Harson V, Levirson JE, Schaller J, Stillman JS. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum 1977; 20 (Suppl): 195-9.
4. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561-6.
5. Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993; 11: 451-6.
6. Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002; 20: 121-3.
7. Ravelli A, Magni-Manzoni S, Foti T, Besana C, Felici E, Trail L, Garay S, Sala E, Pistorio A, Pavia AM. Macrophage activation syndrome in juvenile idiopathic arthritis: towards the development of diagnostic guidelines. Arthritis Rheum 2001; 44 (Suppl): 166.
8. Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 2002; 38: 305-9.
9. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 2918-22.
10. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-9.
11. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750-4.
12. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275-8.
13. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, Naqvi S, Raza R, Patel K, Abramson D, Bruno G, Abramson SB, Amin AR. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res 2000; 49: 20-6.
14. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 1999; 68: 1255-63.
15. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28: 2120-4.